06.23.25 -- Rethinking CGT Biotech Growth & Investment With Audrey Greenberg

Using cells with a pre-engineered TARGATT landing pad, we achieve inducible expression within just 4-6 weeks after donor plasmid creation, significantly reducing development time and effort.

Leverage mass photometry to quickly and accurately monitor the full-to-empty ratio of rAAV samples, ensuring consistent product quality and enhanced safety and efficacy in gene therapy applications.

Gain valuable insights into advanced methods and analysis techniques for high-order structure, physiochemical characterization, cell-based and biochemical assays, and more.

Plan early and align research, development, and commercial priorities to ensure a seamless transition from clinical development to scalable, cost-efficient commercialization.

Review the importance of alternative approaches to viral vector production and the benefits of intensified adherent cell culture for improving efficiency, reducing costs, and accelerating development.

The manufacturing process for autologous therapies is complex and highly customized, requiring well-orchestrated transport, careful planning, and tight control of many discrete and manual processing steps.

Targeted metabolomics-based PAT allows for metabolic profiling of the T-cells throughout the cell therapy manufacturing process through spent media analysis.

Accurately monitoring process parameters and bioreactor performance while leveraging process analytical technologies can lead to strong improvements in productivity, quality, and process stability.

Accelerate access to high-quality, cost-effective lentiviral vectors with our intensified TFDF-based manufacturing platform, delivering multi-fold yield improvements and scalable, space-efficient production.